Specificity of mimotope-induced anti-high molecular weight-melanoma associated antigen (HMW-MAA) antibodies does not ensure biological activity

PLoS ONE

Volumn 6, Issue 5, 2011, Pages

  Latzka, Julia ^a   Gaier, Sonja ^a   Hofstetter, Gerlinde ^a   Balazs, Nina ^a   Smole, Ursula ^a   Ferrone, Soldano ^b   Scheiner, Otto ^a   Breiteneder, Heimo ^a   Pehamberger, Hubert ^c   Wagner, Stefan ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^c Universitatsklinik fur Dermatologie   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; EPITOPE; HIGH MOLECULAR WEIGHT MELANOMA ASSOCIATED ANTIGEN; HIGH MOLECULAR WEIGHT MELANOMA ASSOCIATED ANTIGEN ANTIBODY; KEYHOLE LIMPET HEMOCYANIN; LIGAND; MELANOMA ANTIGEN; MELANOMA VACCINE; MIMOTOPE; MONOCLONAL ANTIBODY; PEPTIDE DERIVATIVE; POLYPEPTIDE; UNCLASSIFIED DRUG; CANCER ANTIBODY; HMW MAA; HMW-MAA; PEPTIDE LIBRARY; TUMOR ANTIGEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIBODY SPECIFICITY; ANTIGEN BINDING; ANTIGEN EXPRESSION; ANTIGENICITY; ARTICLE; BACTERIOPHAGE; BAGG ALBINO MOUSE; BIOLOGICAL ACTIVITY; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; IMMUNOGENICITY; IN VITRO STUDY; MELANOMA CELL; MOUSE; NONHUMAN; PHAGE DISPLAY; RABBIT; ANIMAL; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; IMMUNOHISTOCHEMISTRY; IMMUNOLOGY; TUMOR CELL LINE;

MUS; ORYCTOLAGUS CUNICULUS;

ANIMALS; ANTIBODIES, NEOPLASM; ANTIGENS, NEOPLASM; CELL LINE, TUMOR; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPITOPES; FLOW CYTOMETRY; HUMANS; IMMUNOHISTOCHEMISTRY; MICE; PEPTIDE LIBRARY; RABBITS;

EID: 79955852875     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0019383     Document Type: Article

References (36)

1. Campoli MR, Chang CC, Kageshita T, Wang X, McCarthy JB, et al. (2004) Human high molecular weight-melanoma-associated antigen (HMW-MAA): a melanoma cell surface chondroitin sulfate proteoglycan (MSCP) with biological and clinical significance. Crit Rev Immunol 24: 267-296.
2. Wang X, Wang Y, Yu L, Sakakura K, Visus C, et al. (2010) CSPG4 in cancer: multiple roles. Curr Mol Med 10: 419-429.
3. Chang CC, Campoli M, Luo W, Zhao W, Zaenker KS, et al. (2004) Immunotherapy of melanoma targeting human high molecular weight melanoma-associated antigen: potential role of nonimmunological mechanisms. Ann N Y Acad Sci 1028: 340-350.
4. Mittelman A, Chen ZJ, Liu CC, Hirai S, Ferrone S, (1994) Kinetics of the immune response and regression of metastatic lesions following development of humoral anti-high molecular weight-melanoma associated antigen immunity in three patients with advanced malignant melanoma immunized with mouse antiidiotypic monoclonal antibody MK2-23. Cancer Res 54: 415-421.
5. Mittelman A, Chen ZJ, Yang H, Wong GY, Ferrone S, (1992) Human high molecular weight melanoma-associated antigen (HMW-MAA) mimicry by mouse anti-idiotypic monoclonal antibody MK2-23: induction of humoral anti-HMW-MAA immunity and prolongation of survival in patients with stage IV melanoma. Proc Natl Acad Sci U S A 89: 466-470.
6. Maciag PC, Seavey MM, Pan ZK, Ferrone S, Paterson Y, (2008) Cancer immunotherapy targeting the high molecular weight melanoma-associated antigen protein results in a broad antitumor response and reduction of pericytes in the tumor vasculature. Cancer Res 68: 8066-8075.
7. Zhao L, Liu Z, Fan D, (2008) Overview of mimotopes and related strategies in tumor vaccine development. Expert Rev Vaccines 7: 1547-1555.
8. Bramswig KH, Knittelfelder R, Gruber S, Untersmayr E, Riemer AB, et al. (2007) Immunization with mimotopes prevents growth of carcinoembryonic antigen positive tumors in BALB/c mice. Clin Cancer Res 13: 6501-6508.
9. Riemer AB, Hantusch B, Sponer B, Kraml G, Hafner C, et al. (2005) High-molecular-weight melanoma-associated antigen mimotope immunizations induce antibodies recognizing melanoma cells. Cancer Immunol Immunother 54: 677-684.
10. Riemer AB, Klinger M, Wagner S, Bernhaus A, Mazzucchelli L, et al. (2004) Generation of Peptide mimics of the epitope recognized by trastuzumab on the oncogenic protein Her-2/neu. J Immunol 173: 394-401.
11. Engelhard VH, Bullock TN, Colella TA, Sheasley SL, Mullins DW, (2002) Antigens derived from melanocyte differentiation proteins: self-tolerance, autoimmunity, and use for cancer immunotherapy. Immunol Rev 188: 136-146.
12. Wagner S, Hafner C, Allwardt D, Jasinska J, Ferrone S, et al. (2005) Vaccination with a human high molecular weight melanoma-associated antigen mimotope induces a humoral response inhibiting melanoma cell growth in vitro. J Immunol 174: 976-982.
13. Wagner S, Krepler C, Allwardt D, Latzka J, Strommer S, et al. (2008) Reduction of human melanoma tumor growth in severe combined immunodeficient mice by passive transfer of antibodies induced by a high molecular weight melanoma-associated antigen mimotope vaccine. Clin Cancer Res 14: 8178-8183.
14. Ray S, Chhabra A, Mehrotra S, Chakraborty NG, Ribas A, et al. (2009) Obstacles to and opportunities for more effective peptide-based therapeutic immunization in human melanoma. Clin Dermatol 27: 603-613.
15. Spiridon CI, Ghetie MA, Uhr J, Marches R, Li JL, et al. (2002) Targeting multiple Her-2 epitopes with monoclonal antibodies results in improved antigrowth activity of a human breast cancer cell line in vitro and in vivo. Clin Cancer Res 8: 1720-1730.
16. Wagner S, Jasinska J, Breiteneder H, Kundi M, Pehamberger H, et al. (2007) Delayed tumor onset and reduced tumor growth progression after immunization with a Her-2/neu multi-peptide vaccine and IL-12 in c-neu transgenic mice. Breast Cancer Res Treat 106: 29-38.
17. Giacomini P, Veglia F, Cordiali Fei P, Rehle T, Natali PG, et al. (1984) Level of a membrane-bound high-molecular-weight melanoma-associated antigen and a cytoplasmic melanoma-associated antigen in surgically removed tissues and in sera from patients with melanoma. Cancer Res 44: 1281-1287.
18. Matsui M, Temponi M, Ferrone S, (1987) Characterization of a monoclonal antibody-defined human melanoma-associated antigen susceptible to induction by immune interferon. J Immunol 139: 2088-2095.
19. Wilson BS, Imai K, Natali PG, Ferrone S, (1981) Distribution and molecular characterization of a cell-surface and a cytoplasmic antigen detectable in human melanoma cells with monoclonal antibodies. Int J Cancer 28: 293-300.
20. van Elsas A, Aarnoudse C, van der Minne CE, van der Spek CW, Brouwenstijn N, et al. (1997) Transfection of IL-2 augments CTL response to human melanoma cells in vitro: immunological characterization of a melanoma vaccine. J Immunother 20: 343-353.
21. Chee DO, Boddie AW, Roth JA, Holmes EC, Morton DL, (1976) Production of melanoma-associated antigen(s) by a defined malignant melanoma cell strain grown in chemically defined medium. Cancer Res 36: 1503-1509.
22. Jasinska J, Wagner S, Radauer C, Sedivy R, Brodowicz T, et al. (2003) Inhibition of tumor cell growth by antibodies induced after vaccination with peptides derived from the extracellular domain of Her-2/neu. Int J Cancer 107: 976-983.
23. Felici F, Castagnoli L, Musacchio A, Jappelli R, Cesareni G, (1991) Selection of antibody ligands from a large library of oligopeptides expressed on a multivalent exposition vector. J Mol Biol 222: 301-310.
24. Holmes K, Lantz LM, Fowlkes BJ, Schmid I, Giorgi JV, (2001) Preparation of cells and reagents for flow cytometry. Curr Protoc Immunol Chapter 5: Unit 5.3.
25. Brunner R, Jensen-Jarolim E, Pali-Scholl I, (2010) The ABC of clinical and experimental adjuvants-a brief overview. Immunol Lett 128: 29-35.
26. Hafner C, Wagner S, Allwardt D, Riemer AB, Scheiner O, et al. (2005) Cross-reactivity of mimotopes with a monoclonal antibody against the high molecular weight melanoma-associated antigen (HMW-MAA) does not predict cross-reactive immunogenicity. Melanoma Res 15: 111-117.
27. Yang X, Yu X, (2009) An introduction to epitope prediction methods and software. Rev Med Virol 19: 77-96.
28. Campoli M, Ferrone S, Wang X, (2010) Functional and clinical relevance of chondroitin sulfate proteoglycan 4. Adv Cancer Res 109: 73-121.
29. Li M, Yan Z, Han W, Zhang Y, (2006) Mimotope vaccination for epitope-specific induction of anti-CD20 antibodies. Cell Immunol 239: 136-143.
30. Perosa F, Favoino E, Caragnano MA, Dammacco F, (2005) CD20 mimicry by a mAb rituximab-specific linear peptide: a potential tool for active immunotherapy of autoimmune diseases. Ann N Y Acad Sci 1051: 672-683.
31. Perosa F, Favoino E, Vicenti C, Guarnera A, Racanelli V, et al. (2009) Two structurally different rituximab-specific CD20 mimotope peptides reveal that rituximab recognizes two different CD20-associated epitopes. J Immunol 182: 416-423.
32. Perosa F, Favoino E, Vicenti C, Merchionne F, Dammacco F, (2007) Identification of an antigenic and immunogenic motif expressed by two 7-mer rituximab-specific cyclic peptide mimotopes: implication for peptide-based active immunotherapy. J Immunol 179: 7967-7974.
33. Hartmann C, Muller N, Blaukat A, Koch J, Benhar I, et al. (2010) Peptide mimotopes recognized by antibodies cetuximab and matuzumab induce a functionally equivalent anti-EGFR immune response. Oncogene 29: 4517-4527.
34. Riemer AB, Kurz H, Klinger M, Scheiner O, Zielinski CC, et al. (2005) Vaccination with cetuximab mimotopes and biological properties of induced anti-epidermal growth factor receptor antibodies. J Natl Cancer Inst 97: 1663-1670.
35. Jiang B, Liu W, Qu H, Meng L, Song S, et al. (2005) A novel peptide isolated from a phage display peptide library with trastuzumab can mimic antigen epitope of HER-2. J Biol Chem 280: 4656-4662.
36. Hafner C, Breiteneder H, Ferrone S, Thallinger C, Wagner S, et al. (2005) Suppression of human melanoma tumor growth in SCID mice by a human high molecular weight-melanoma associated antigen (HMW-MAA) specific monoclonal antibody. Int J Cancer 114: 426-432.